## Julie Ho

## List of Publications by Citations

Source: https://exaly.com/author-pdf/6387677/julie-ho-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 2,464 22 49 g-index

60 3,011 4.3 4.61 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
59	Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 1157-67	8.7	672
58	Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. <i>American Journal of Transplantation</i> , <b>2015</b> , 15, 2921-30	8.7	223
57	Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 3114-22	8.7	221
56	Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. <i>American Journal of Kidney Diseases</i> , <b>2009</b> , 53, 584-95	7.4	155
55	Urinary, Plasma, and Serum BiomarkersWitility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 993-1005	7.4	144
54	Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 3353-3362	12.7	125
53	HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 1708-1719	8.7	64
52	Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. <i>American Journal of Kidney Diseases</i> , <b>2012</b> , 59, 196-201	7.4	57
51	Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. <i>Transplantation</i> , <b>2011</b> , 92, 878-82	1.8	57
50	Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 1811-23	8.7	52
49	Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 703-711	8.7	51
48	Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 2340-6	6.9	50
47	Early reversible acute kidney injury is associated with improved survival in septic shock. <i>Journal of Critical Care</i> , <b>2014</b> , 29, 711-7	4	49
46	Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. <i>Transplantation</i> , <b>2010</b> , 90, 394-400	1.8	46
45	Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. <i>Transplantation</i> , <b>2015</b> , 99, 797-804	1.8	45
44	Immune monitoring of kidney allografts. American Journal of Kidney Diseases, 2012, 60, 629-40	7.4	32
43	Pre-transplant ATR antibodies correlate with early allograft rejection. <i>Transplant Immunology</i> , <b>2018</b> , 46, 29-35	1.7	30

## (2015-2014)

1.8 2.3 5	27 23
5	22
7.4	
	22
8.7	20
1.8	19
1.8	19
8.7	17
1.8	17
2.3	16
1.5	15
<b>28</b> 5	14
2.3	13
2.7	12
3.2	11
1.8	10
2.3	10
	3.7 1.8 1.8 1.5 2.3 2.7 3.2

24	The prognostic value of urinary chemokines at 6 months after pediatric kidney transplantation. <i>Pediatric Transplantation</i> , <b>2018</b> , 22, e13205	1.8	9
23	Early Antibody-Mediated Kidney Transplant Rejection Associated With Anti-Vimentin Antibodies: A Case Report. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 75, 138-143	7.4	8
22	Validity and utility of urinary CXCL10/Cr immune monitoring in pediatric kidney transplant recipients. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1545-1555	8.7	8
21	Improving the Prediction of Cardiac Surgery-Associated Acute Kidney Injury. <i>Kidney International Reports</i> , <b>2017</b> , 2, 172-179	4.1	7
20	Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. <i>BMJ Open</i> , <b>2019</b> , 9, e024908	3	7
19	Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement. Transplantation Direct, <b>2020</b> , 6, e519	2.3	6
18	A proteomic evaluation of urinary changes associated with cardiopulmonary bypass. <i>Clinical Proteomics</i> , <b>2016</b> , 13, 17	5	6
17	Activity-Based Protein Profiling of Intraoperative Serine Hydrolase Activities during Cardiac Surgery. <i>Journal of Proteome Research</i> , <b>2018</b> , 17, 3547-3556	5.6	6
16	New developments in transplant proteomics. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2017</b> , 26, 229-234	3.5	5
15	Activity-based Protein Profiling Approaches for Transplantation. <i>Transplantation</i> , <b>2019</b> , 103, 1790-1798	1.8	3
14	Atypical pneumonia due to human bocavirus in an immunocompromised patient. <i>Cmaj</i> , <b>2017</b> , 189, E697	-5699	2
13	Atypical cells in a voided urine cytology specimen in a renal transplant recipient. <i>Diagnostic Cytopathology</i> , <b>2017</b> , 45, 69-72	1.4	2
12	The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. <i>American Journal of Transplantation</i> , <b>2021</b> ,	8.7	2
11	Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies. Transplantation Direct, <b>2019</b> , 5, e477	2.3	2
10	Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation. <i>Clinical Proteomics</i> , <b>2020</b> , 17, 23	5	1
9	Spinal cord compression from a brown tumour despite maximal medical therapy with cinacalcet and sevelamer. <i>CKJ: Clinical Kidney Journal</i> , <b>2008</b> , 1, 151-3	4.5	1
8	Early surveillance biopsy utilization and management of pediatric renal allograft acute T cell-mediated rejection in Canadian centers: Observations from the PROBE multicenter cohort study. <i>Pediatric Transplantation</i> , <b>2021</b> , 25, e13870	1.8	1
7	Lifelong, universal Pneumocystis jirovecii pneumonia prophylaxis: Patient uptake and adherence after kidney transplant. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13509	2.7	O

## LIST OF PUBLICATIONS

6	A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1503-1512	8.7	О
5	Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2021</b> , 8, 20543581211033496	2.3	O
4	Training Programs for Fundamental and Clinician-Scientists: Balanced Outcomes for Graduates by Gender. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2021</b> , 8, 20543581211033405	2.3	O
3	Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multi-center cohort of Canadian pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , <b>2021</b> , 25, e13959	1.8	
2	Phospholipase A2 group XV activity during cardiopulmonary bypass surgery. <i>Clinical Biochemistry</i> , <b>2021</b> , 88, 49-55	3.5	
1	Waitlisted and Transplant Patient Perspectives on Expanding Access to Deceased-Donor Kidney Transplant: A Qualitative Study. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2022</b> , 9, 2054358122110	)ð2 <sup>3</sup>	